Drug resistance is the leading cause of death in cervical cancer patients and has been a major challenge in cervical cancer treatment.268–271 Ruiz-Herrera A et al. detected that deficiency in the HR protein RAD54 resulted in a marked increase in DM-containing subpopulations in cervical cancer cell-derived MTX-resistant subclones. Here, HR is linked to cervical carcinoma.